1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Bal Pharma Limited

Bal Pharma Limited

84.57
INR
-2.73
(-3.13%)
4.57EPS
17.49P/E
1.27BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
168.04
146.22
151.35
158.24
146.74
155.67
118.31
173.92
188.71
192.29
207.36
185.63
190.31
211.04
Basic EPS, GAAP
4.77
2.83
1.09
1.24
1.96
2.67
-8.62
3.34
3.79
1.64
4.7
4.55
3.95
4.55
Free Cash Flow per Basic Share
5.5
6.96
-26.07
-1.3
-2.26
-0.59
12.83
13.36
12.36
-10.31
7.51
0.96
5.31
- -
Dividend per Share
0.87
1.18
1.18
1.19
1.19
1.04
1
- -
1
0.99
1
1.21
1.2
- -
Book Value per Share
45.04
42.88
44.04
44.06
45.86
47.02
36.99
36.15
37.65
40.66
45.56
48.63
51.65
- -
Tangible Book Value per Share
40.66
39.1
40.45
40.77
39.99
40.29
29.75
28.67
30.06
31.55
35.94
38.69
40.81
- -
Basic Weighted Avg Shares
11
13
13
14
14
14
14
14
15
16
16
16
16
16
Sales/Revenue/Turnover
1,789
1,872
1,948
2,243
2,080
2,206
1,677
2,469
2,797
3,017
3,263
2,943
3,030
3,344
Operating Margin (%)
7.34
5.78
4.03
3.71
5.08
5.23
-1.57
6.92
5.38
5.82
6.67
6.83
7.56
6.71
Depreciation Expense
47
70
70
65
68
62
2
95
90
91
101
98
111
113
Net Income, GAAP
51
36
14
18
28
38
-122
47
56
26
74
72
63
72
Effective Tax Rate (%)
23.45
25.05
90.21
113.79
86.94
- -
- -
- -
37.87
44.84
17.7
- -
- -
- -
Profit Margin (%)
2.84
1.94
0.72
0.78
1.34
1.72
-7.29
1.92
2.01
0.85
2.27
2.45
2.07
2.15
Working Capital
83
128
148
213
304
198
16
116
189
188
311
154
130
- -
LT Debt
80
66
159
178
347
288
243
255
293
317
377
327
375
- -
Total Equity
500
552
565
601
602
602
453
534
585
637
720
774
823
- -
Return on Invested Capital (%)
10.51
7.67
0.62
-0.76
0.84
- -
- -
- -
6.44
5.27
8.65
- -
- -
- -
Return on Capital (%)
9.99
7.08
2.49
2.01
3.89
- -
- -
- -
6.68
4.59
8.74
- -
- -
- -
Return on Common Equity (%)
10.72
6.89
2.51
2.95
4.37
5.76
-20.52
8.95
10
4.2
10.89
9.66
7.87
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
1,291
- -
LT Borrowings
- -
319
- -
LT Finance Leases
- -
56
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
16
16
Market Capitalization
1,167
962
1,267

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
2,622
- -
Cash, Cash Equivalents & STI
- -
92
- -
Accounts Receivable, Net
- -
936
- -
Inventories
- -
1,164
- -
Total Current Liabilities
- -
2,492
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,291
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.49%
9.07%
6.26%
Free Cash Flow
-236.21%
0.28%
453.26%
Net Income, GAAP
-30.55%
27.26%
-12.91%
Sales/Revenue/Turnover
5.96%
4.49%
2.96%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
744
737
732
819
2,943
2026
659
740
877
841
3,030
2027
886
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.16
0.65
0.33
3.4
4.55
2026
0.13
0.45
1.12
2.26
3.95
2027
0.71
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1.21
2026
- -
- -
- -
- -
1.2
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Shailesh Dheerajmal Siroya
Full Time Employees
939
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Lakshmi Narayan Complex Bangalore KA India 560052
IPO Date
Feb 1, 1995
Website
balpharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Bal Pharma Limited is an integrated pharmaceutical company headquartered in Bangalore, India, specializing in the manufacturing and marketing of active pharmaceutical ingredients (APIs), pharmaceutical formulations, and finished dosage forms. The company’s product portfolio includes prescription drugs, generic medicines, over-the-counter (OTC) products, intravenous infusion products, Ayurvedic medicines, bulk actives, and pharmaceutical intermediates. It operates multiple manufacturing units across India, including specialized API production facilities and formulation plants. Therapeutic focus areas encompass anti-diabetes, anti-histamine, anti-inflammatory, gastroenterology, cardiology, dermatology, respiratory care, women's health, anti-infectives, pain management, skin care, bone health, and cardiac care. Notable brands include Stonex, Ashwamed, Prostowin, Suswas, Menoleap, Ayursulin in the Ayurvedic segment; Secremet and Servace for cardiac care; and Diabend and Sitabend for diabetic care. The company has a strong presence in domestic and international markets, supplying to over 80 countries, including non-regulated, semi-regulated, and increasingly regulated markets. Recent major developments include the commencement of a greenfield API project at Kadechur KIADB Industrial Area in Yadgir District, Karnataka, aimed at expanding its bulk drug manufacturing capacity. In 2023, Bal Pharma launched Sitagliptin-based products under the brand names SITABEND and SITABEND-M, strengthening its diabetic care portfolio. The company completed the merger with Golden Drugs Private Limited, enhancing its manufacturing and operational scale. Bal Pharma is focused on vertical integration with investments in multiple facilities including IV units, API production, and formulation units at Pune, Bangalore, Rudrapur, and Sangli. These expansions aim to enhance production capabilities and support its strategic growth in both domestic and international pharmaceutical sectors. Founded in 1987, Bal Pharma continues to invest in innovative solutions and product diversification within the pharmaceutical industry while maintaining a commitment to providing high-quality, safe, and affordable medicines.